PFE - Pfizer Inc.
42.33 0.00 (0.00%)
After hours: 7:55PM EDT
| Previous Close | 42.09 |
| Open | 42.20 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 900 |
| Day's Range | 42.09 - 42.77 |
| 52 Week Range | 32.32 - 42.77 |
| Volume | 21,367,175 |
| Avg. Volume | 20,349,579 |
| Market Cap | 248.143B |
| Beta | 0.96 |
| PE Ratio (TTM) | 11.31 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.36 (3.23%) |
| Ex-Dividend Date | 2018-08-02 |
| 1y Target Est | N/A |
- Market Realist•5 hours ago
Amgen’s Product Performance in Q2 2018
Amgen’s (AMGN) product portfolio includes the blockbuster drugs Prolia, Enbrel, Neulasta, Xgeva, Aranesp, Sensipar/Mimpara, Kyprolis, and Epogen. Blockbuster drug Neulasta (pegfilgrastim) reported a 1% rise in revenue to $1.10 billion during the second quarter compared to ~$1.09 billion in the second quarter of 2017.
- Bloomberg•9 hours ago
Drugmakers Extend Summer Rally as Markets Regain Footing
Major pharmaceutical companies are partying like it’s 2001. U.S. drugmakers including Pfizer Inc., Eli Lilly & Co., and Merck & Co. are seeing their share prices balloon to the highest levels in more than 16 years as investors rotate in after second-quarter results proved stronger than expected. Impressive earnings paired with waning concerns about potential Trump administration actions on drug pricing could be helping to draw generalist investors in a bit of a “catch up trade,” according to Credit Suisse analyst Vamil Divan.
Market Realist•12 hours agoArray BioPharma’s Immuno-Oncology Collaborations: Trial Update
Array BioPharma (ARRY) is developing a number of combination therapies with its investigational MEK inhibitor binimetinib with PD-1/PD-L1 checkpoint inhibitors. The company is conducting the trials in collaboration with Bristol-Myers Squibb (BMY), Pfizer (PFE), and Merck (MRK). During its fourth-quarter and full-fiscal 2018 earnings release on August 14, Array Biopharma provided updates on these trials.
Market Realist•12 hours agoMylan Cuts Its Fiscal 2018 Guidance, Citing US Market Challenges
Mylan (MYL) made a downward revision to its fiscal 2018 guidance during its second-quarter earnings release on August 8. A major factor driving down the company’s performance was lower North America sales due to volume declines in the company’s existing products. Due to the impact of “turbulence in the U.S. and the disturbing trends regarding access to complex products,” Mylan lowered its fiscal 2018 guidance during its second-quarter earnings release on August 8.
Market Realist•13 hours agoMylan Has a Strong Balance Sheet despite Weak Q2 Performance
Mylan (MYL) ended the second quarter with cash and cash equivalents of $330.2 million. This compared to the net cash provided by operating activities of $1.02 billion available to the company by the end of the fiscal second quarter of 2017. For the six months ended June 30, Mylan’s adjusted free cash flows were $1.3 billion, up ~22% YoY (year-over-year).
- Motley Fool•14 hours ago
3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro
The company gives its thoughts on the drug's label, market size, and price.
Market Realist•15 hours agoNon-Opioid Pain Therapy Market Opportunity for Teva
On August 16, Teva announced positive top-line data for its NGF-inhibitor Fasinumab, which is being developed in collaboration with Regeneron. Teva’s stock price rise was also boosted by the FDA approval of Teva’s generic version of EpiPen, which we covered in FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%. Teva also has Fremanezumab in its product pipeline, which is expected to be a key growth driver for the company and is being developed for the treatment of migraines.
- Market Realist•15 hours ago
Allergan’s US Specialized Therapeutics Segment in Q2 2018
Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products, including eye care products, medical esthetics products, dermatology products, neuroscience products, and urology products.
- Motley Fool•2 days ago
Is Viking Therapeutics, Inc. a Buy?
No gnashing of teeth needed to make a call on this clinical-stage biotech.
- Motley Fool•3 days ago
Here’s Why Alnylam’s Shares Are Tumbling
Alnylam secured a first-in-class approval, but that doesn’t guarantee commercial success.
- Investor's Business Daily•3 days ago
Retailer Breaks Out As This Dow Jones Stock Is A New Emerging Winner
The Dow Jones industrial average led a light yet broad rally in stocks today. Chip stocks weighed on the leading index of growth companies. Pfizer is gaining more traction.
- Motley Fool•3 days ago
2 Reasons Alnylam Stock Fell on a Landmark Drug Approval
Investors didn't celebrate Alnylam's first drug approval. Maybe they should have.
- Investopedia•3 days ago
Pfizer, at Highest Price in a Decade, May Fall 10%
Pfizer Inc's ( PFE) stock has surged higher by more than 16% in 2018. Now shares may be due to fall by about 10% based on technical analysis. The technical chart shows Pfizer's stock breaking out at the start of July when it increased above technical resistance at $37 and has risen by more than 13% since. Now shares are bumping up against a resistance level around $42, that goes back for nearly two decades to late 2001, and that may prove difficult for the stock to rise above.
- Motley Fool•3 days ago
3 Tough-Luck Tumbles in Healthcare: Are They Buys?
Spark Therapeutics, Rite Aid, and Alnylam Pharmaceuticals shares have dropped recently, but that doesn't necessarily make all three stocks worth buying.
Market Realist•3 days agoMylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
Mylan’s (MYL) epinephrine auto-injector EpiPen is approved as the first line of treatment for life-threatening allergic reaction anaphylaxis. During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.
- Bloomberg•3 days ago
Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies
Mylan NV’s EpiPen is still hard to find at many pharmacies, three months after U.S. authorities declared that the lifesaving allergy device was in shortage, a survey by Wells Fargo & Co. showed. The finding comes a day after Teva Pharmaceutical Industries Ltd. gained Food and Drug Administration approval to sell a generic version of Mylan’s epinephrine autoinjector. Wells Fargo analysts reached out to 53 pharmacies across the country on Thursday and found that 66 percent were out of stock of Mylan’s EpiPens, not including EpiPen Jr., analyst Davis Maris said in a note Friday.
- Zacks•3 days ago
Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic
Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.
- CNBC•4 days ago
EpiPen shortage has parents struggling during back-to-school season
The life-saving allergy medicine has had manufacturing disruptions since May, but allergy sufferers and caregivers may find it especially hard to find now, as parents try to stock up to send their kids back to school.
Markit•4 days agoSee what the IHS Markit Score report has to say about Pfizer Inc.
Pfizer Inc NYSE:PFE
- Motley Fool•4 days ago
If I Had to Buy 1 Stock in August, It Would Be This One
This healthcare company appears poised to turn a corner.
- Zacks•4 days ago
Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study
Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.
Market Realist•4 days agoFDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
Today, Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr. The epinephrine autoinjector is used to treat allergic reactions, including life-threatening condition of anaphylaxis. The company received FDA approval for the use of the product in adults as well as children weighing more than 33 pounds. In 2016, Teva’s generic version of EpiPen was unable to secure FDA approval.
- Motley Fool•5 days ago
3 Terrible Reasons to Sell Pfizer Stock
Pfizer's shares have been heating up, but now isn't the time to take profits. Here's why.
- CNBC Videos•4 days ago
Cramer throws out this tech stock to diversify portfolio
Jim Cramer answers callers' questions about how to diversify their portfolios, including which tech stocks to keep and which to throw out.
